SPRY240517C12500
- 0.03
- 0.000.00%
ARS Pharmaceuticals Newsroom
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Sells US$905.44K in Common Stock
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder Lowenthal Richard E sold 100K shares of common stock on May 14, 15, 16, 2024 at an average price of $9.0544 for a total value of $905.44K. This transacti
Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)
ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns With EPS Projections Amidst Regulatory ...
ARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 Loss per Share (Vs US$0.16 Loss in 1Q 2023)
ARS Pharmaceuticals Unveils Updated Corporate Presentation
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Sells US$934.37K in Common Stock
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder Lowenthal Richard E sold 100K shares of common stock on May 7, 2024 at an average price of $9.3437 for a total value of $934.37K. This transaction involv
Express News | ARS Pharmaceuticals Inc: Qtrly Net Loss per Share, Basic and Diluted $0.11
Express News | ARS Pharmaceuticals Inc: $223.6 Mln in Cash and Securities as of March 31, Providing an Expected Operating Runway of at Least Three Years
Express News | ARS Pharmaceuticals Inc: Neffy Nda and Crl Response Under Review by FDA With Anticipated Review Completion by Early October 2024
Express News | ARS Pharmaceuticals Inc: Response Submitted for Neffy Marketing Authorization Application (Maa) to Ema's Chmp; Chmp Opinion Expected in Q2 of 2024
Express News | ARS Pharmaceuticals Inc: Preparing to Initiate Outpatient Study of Neffy for Urticaria (Hives) in Second Half of 2024
ARS Pharmaceuticals | 10-Q: Quarterly report
Express News | ARS Pharmaceuticals Q1 Operating Expenses USD 13.192 Million
Express News | ARS Pharmaceuticals Q1 Basic EPS USD -0.11
Express News | CSL - Under the Terms of Agreement, ARS Pharma Will Be Responsible for Manufacturing and Product Supply of Neffy
Express News | CSL Ltd - Under Deal, CSL Seqirus Will Be Responsible for Applying for Regulatory Approval, Reimbursement and Commercialisation of Neffy
Express News | ARS Pharmaceuticals Inc: Chmp Opinion on Neffy Marketing Authorization Application Anticipated in Q2 of 2024
Express News | ARS Pharmaceuticals Submits Response for Neffy® (Epinephrine Nasal Spray) Marketing Authorization Application to Ema’s Chmp and Enters License Agreement With CSL Seqirus for Commercialization of Neffy in Australia and New Zealand
Insider Trading: ARS Pharmaceuticals' (NASDAQ:SPRY) Insiders Buy Shares Worth $679K
Market Sentiment Around Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. ARS Pharmaceuticals, Inc., a biopharmaceutica